Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Acta Haematol ; 133(2): 221-5, 2015.
Article in English | MEDLINE | ID: mdl-25376208

ABSTRACT

Primary lymphoma of the lung or pleural is a very rare condition. Due to the outdated literature data, the approximate occurrence of primary and secondary lung and/or pleural involvement according to the most common B cell lymphoma entities is unknown. To answer this open question in Austria, we screened the Tyrolean registry for B cell non-Hodgkin's lymphomas regarding primary and secondary lung involvement. Of 854 patients affected by B cell lymphoma, 7.5% had lung/pleural disease. This organ was the primary site in only 0.7%, while a secondary involvement was registered in 6.8%. Most of them were affected by diffuse large B cell lymphoma (DLBCL; 29/368, 8%) followed by follicular lymphoma (7/188, 4%), mantle cell lymphoma (7/57, 12%), mucosa-associated tissue lymphoma (10/37, 27%), posttransplant lymphoproliferative disease (6/24, 25%), Burkitt lymphoma (3/19, 16%), other lymphomas (1/32, 3%) and Richter transformation (1/11, 9%). Moreover, primary lung/pleural lymphoma is one of the rarest neoplasias affecting the lung, accounting for only 0.4% of cases. Lung/pleural involvement is a very rare condition among B cell lymphomas since it mainly occurs in the setting of a generalized disease. A large majority of patients with secondary organ involvement are affected by DLBCL and have similar clinical features at diagnosis to others with advanced-stage disease.


Subject(s)
Lung Neoplasms/pathology , Lymphoma, B-Cell/pathology , Pleural Neoplasms/pathology , Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Lung Neoplasms/epidemiology , Lymphoma, B-Cell/epidemiology , Male , Middle Aged , Neoplasm Staging , Pleural Neoplasms/epidemiology
3.
Eur J Pharm Sci ; 15(1): 11-20, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11803127

ABSTRACT

Diphenylmethyleneaminooxycarboxylic acids were found to represent novel type inhibitors of the enzyme aldose reductase. Ester derivatives of the most active compound (3c) (IC(50)=33 microM) were prepared as potential prodrugs and the rate of degradation was studied by treatment with buffers, plasma, and various hydrolytic enzymes. Whereas all compounds were not hydrolysed at physiological pH, incubation in the presence of enzyme led to hydrolysis. The rate of enzymatic degradation, however, depended on the nature of the ester function. Whereas the isopropyl ester (4) turned out to be the most stable compound, the ethyl ester (2c) could be cleaved in the presence of esterase and lipase, respectively. The benzylic and aromatic esters were found to be hydrolysed rapidly in the presence of lipase (benzyl ester, 7), or in plasma, by cholinesterase and esterase (phenyl ester, 6), respectively.


Subject(s)
Aldehyde Reductase/antagonists & inhibitors , Benzhydryl Compounds/chemistry , Carboxylic Acids/chemistry , Enzyme Inhibitors/chemistry , Prodrugs/chemistry , Aldehyde Reductase/metabolism , Animals , Benzhydryl Compounds/pharmacology , Carboxylic Acids/pharmacology , Cattle , Enzyme Inhibitors/pharmacology , Hydrolysis , Prodrugs/pharmacology , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...